David A. Siegel Denali Therapeutics Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 15,100 shares of DNLI stock, worth $240,845. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,100Holding current value
$240,845% of portfolio
0.0%Shares
15 transactions
Others Institutions Holding DNLI
# of Institutions
240Shares Held
121MCall Options Held
80KPut Options Held
36.8K-
Black Rock Inc. New York, NY13.2MShares$210 Million0.01% of portfolio
-
Baillie Gifford & CO12.3MShares$196 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$192 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA9.85MShares$157 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.48MShares$87.4 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.14B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...